1IAVI database of AIDS vaccines in human trials[EB/OL].http://www.iavireport.org/trialsdb
2Mascola JR,Snyder SW,Weislow OS,et al.Immunization with envelope subunit vaccine products elicits neutralizing antibodics against laboratoryadapted but not primary isolates of human immunodeficiency virus type 1.The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group[J].J Infect Dis,1996,173:340 -348.
3Mitka M.Critics bash HIV vaccine trial analysis[J].Jama,2003,289:1491.
4Check E.Army HIV vaccine to undergo clinical trial as rival is halted[J].Nature,2002,416:6.
6Frantz S.Scientists slam rationale behind largest HIV vaccine trial.[J]Nat Rev Drug Discov,2004,3:195.
7Mwau M,Cebere I,Sutton J,et al.A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials:stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccinas in humans[J].J Gen Virol,2004,85:911-919.
8Jaoko W.Safety and immunogenicty of DNA and MVA HIVA Vaccines in phase I HIV-1 vaccine trials in Nairobi,Kenya[C].AIDS Vaccine 04 Conference Lausanne Switzerland.WWW.AIDSVaccine 04.org.
9Emini,E.A.Ongoing development and evaluation of a potential HIV-1 vaccine using a replication-defective adenoviral vector[C].Presented at the Keystone Symposium on HIV-1 Vaccine Development,2003,Banff,Canada.
10Morral N,O'Neal WK,Rice K,et al.Beaudet,end C.Langston.Lethal toxicity,severe endothelial injury,and a threshold effect with high doses of an adenoviral vector in baboons[J].Hum.Gene Ther,2002,13:143-154.
